~~<i id='44400A5BCE'><strike id='44400A5BCE'><tt id='44400A5BCE'><pre id='44400A5BCE'></pre></tt></strike></i>~~

Home» Wikipedia» knowledge

knowledge

author：fashion 2025-09-30 23:35:13 Page View：5346

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： The cancer drug shortage isn’t new — and neither are the solutions

explore

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

2:34AUkrainiansoldierobserveshissurroundingfromashelteronthefrontlineintheZaporizhzhiaregion,Ukraine